August 12, 2016
Tel Aviv, Israel-based BioLineRx Ltd. announced that Philip A. Serlin has been named Chief Executive Officer, effective October 10, 2016. Mr. Serlin joined the company in 2009 as Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who has served as CEO since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.